Navigation Links
DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
Date:6/8/2013

Chicago, IL (PRWEB) June 08, 2013

The birth control information center at DrugRisk.com is announcing new information on the site for women who have taken the contraceptives Yaz or Yasmin. Records show the number of pending cases filed alleging blood clots has decreased as Bayer reserves compensation for victims*.

DrugRisk was created to improve the safety of patients taking popular prescription drugs like Yaz and Yasmin, by providing the latest research, safety alerts, recalls and litigation news. Visitors can determine if others have experienced similar side effects and decide if they need legal advice.

The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, such as Yaz and Yasmin, can increase the risk of blood clots.

Due to the number of patients that have filed a Yaz lawsuit alleging blood clots, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).

DrugRisk has learned that Bayer has spent nearly $1 billion so far to settle around 4,800 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)****. They have also committed up to $1.5 billion to resolve all the cases*****.

Now, the resource center has learned that the latest court update from the Judicial Panel on Multidistrict Litigation shows the number of filed claims has fallen to 9,961*.

Lawyers are still helping those who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin. Anyone affected is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.

Due to the specialized nature of federal MDL drug injury litigation, DrugRisk cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 5/15/13; jpml.uscourts.gov/sites/jpml/files/Pending%20MDL%20Dockets_By%20District_May-14-2013.pdf
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****Bayer 2/28/13; annualreport2012.bayer.com/en/legal-risks.aspx
*****Reuters, 3/4/13; newsandinsight.thomsonreuters.com/Legal/News/2013/03_-_March/Bayer_reserves_$1_5_bln_to_cover_Yasmin,_Yaz_lawsuits/

Read the full story at http://www.prweb.com/releases/yaz-side-effects/settlement-values/prweb10812345.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
2. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
3. DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits
4. Latest Court Records Show 6% Increase In NuvaRing Lawsuits, DrugRisks Notes
5. DrugRisk News: Federal Panel Issues Latest Mirena Lawsuit Updates
6. DrugRisks Update: Latest Court Figures Show Rise In Pradaxa Lawsuits
7. DrugRisks Update: Yaz Class Action Begins in Canada as Settlements Continue in U.S.
8. DrugRisk Update: Byetta Maker Agrees With Transferring Lawsuits to Federal Court
9. DrugRisks Update: Warning Added to Pradaxa For Blood Condition
10. DrugRisks Update: Use of NuvaRing Drops Amid Injury Allegations
11. DrugRisk Update: New Study Warns of Cancer in Byetta Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and ... high-quality results and maintaining GMP and USP compliance. In a new webinar from ... GMP requirements " these requirements are explained. The challenge is to determine ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... the Self-Funding Success website has recently developed and published an informational resource that ... was created based on common inquiries the site’s team of third party administrator ...
(Date:3/28/2017)... ... ... A minimally invasive porcelain veneer is increasing in popularity ... Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive dentistry, ... and technicians that create these veneers. , According to National Board for ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... BOSTON , March 27, 2017 /PRNewswire/ ... through a data-driven, biological research approach, today ... contributed to the discovery of new data ... and facilitate brown fat metabolism. Joslin Diabetes ... its Interrogative Biology® platform for analysis of ...
(Date:3/27/2017)... -- On Friday, benchmark US indices were ... trading session up 0.19%; the Dow Jones Industrial Average ... 0.08%. US markets made broad based gains with five ... Pre-market today, Stock-Callers.com reviews these four Medical Appliances & ... Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: MDXG), and ...
(Date:3/27/2017)... , March 27, 2017  Allergan plc, ... Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company ... therapies based upon tetracycline chemistry, announced that two ... treatment of moderate to severe acne met their ... once-daily, oral, narrow spectrum tetracycline-derived antibiotic with anti-inflammatory ...
Breaking Medicine Technology: